Overview
RDHL market data
Price History
RDHL price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.00 Diluted earnings per share over the trailing twelve months.
- Beta
- 4.99 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $0.63 – $2.79 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $4.3 · P/B 1.10 · P/S 0.98.
Company News
RedHill Biopharma Says Ebola Outbreak Grows To 3221 Cases, 1407 Deaths; Opaganib Development And Partnership Talks Ongoing With African Medicines Agency, Ugandan Health MinistryBenzinga · Jul 28, 2026, 11:11 AM
RedHill Biopharma Commences ~$6M Offering Of American Depositary Shares, Series A-2 Warrants At $0.70/ADSBenzinga · Jun 18, 2026, 12:10 PM
Redhill Biopharma Announces FDA Rare Pediatric Disease Designation For Opaganib For The Treatment Of NeuroblastomaBenzinga · Jun 9, 2026, 11:10 AM
U.S. State Dept Announces Nearly $38M In Additional Funding Toward The Department's Ongoing Ebola Response EffortsBenzinga · Jun 5, 2026, 6:30 PM
RedHill Biopharma Engages WHO Solidarity Platform And Pharma Partners To Advance Opaganib As Oral Host Directed Therapy For Ebola Virus Disease Amid Bundibugyo Outbreak Showing Preclinical Filovirus Activity And Prior Phase 3 Antiviral ResultsBenzinga · Jun 3, 2026, 4:15 PM
RedHill Biopharma Actively Discussing Potential Collaborations For Advancement Of Its Investigational Oral Drug, Opaganib, To Combat Ebola Virus DiseaseBenzinga · Jun 2, 2026, 12:10 PM